REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight TimeH.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a. ...

Financial Results Announcement - Coherus Oncology will release its second quarter 2025 financial results after market close on August 7, 2025 [1] - A conference call and webcast will be hosted by Coherus' management team starting at 5:00 p.m. EDT on the same day to discuss the financial results and provide a business update [1][3] Webcast and Access Information - A replay of the webcast will be available on the Coherus investor website following the live conference call [2] - The press release with the financial results and related materials will be accessible on the investor website before the conference call begins [3] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI, and a promising pipeline including two mid-stage clinical candidates targeting various cancers [6] - The company aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance new indications in combination with pipeline candidates and partners [6] Pipeline and Research Focus - Coherus' pipeline includes multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is in Phase 1b studies for advanced solid tumors, while Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in multiple studies for various cancers [7]

Core Viewpoint - Coherus Oncology has rebranded itself to emphasize its commitment to innovative immuno-oncology therapies, focusing on combination therapies to enhance cancer treatment outcomes [1][2]. Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with a focus on proprietary immuno-oncology medicines [1][10]. - The company has an approved next-generation PD-1 inhibitor, LOQTORZI, which is the only FDA-approved treatment for recurrent or metastatic nasopharyngeal carcinoma in combination with chemotherapy [5][10]. Pipeline and Development - Coherus is developing a portfolio of novel combination therapies aimed at overcoming immune resistance to existing treatments [4]. - LOQTORZI serves as the foundation of the company's immuno-oncology franchise, with ongoing development for additional tumor types [5][10]. - CHS-114, a selective cytolytic CCR8 antibody, is in Phase 1b studies in combination with toripalimab for advanced solid tumors [6]. - Casdozokitug, an IL-27 antagonist, is being evaluated in a randomized Phase 2 study for advanced metastatic hepatocellular carcinoma [7]. Scientific Expertise - The company is supported by a world-class team with deep expertise in oncology drug development, including members from prestigious institutions and companies [8]. - The Scientific Advisory Board includes experts in Treg immunology and cytokine biology, providing valuable insights for navigating the oncology landscape [8].

Core Insights - Coherus BioSciences, Inc. will release its first quarter 2025 financial results on May 12, 2025, after market close [1] - A conference call and webcast will be held at 5:00 p.m. EDT on the same day to discuss the financial results and provide a business update [1][3] - The press release and related materials will be available on the company's investor website prior to the conference call [3][4] Company Overview - Coherus is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a growing revenue stream [6] - The company has a promising pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [6] - Coherus aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance new indications in combination with its pipeline candidates and partners [6] Pipeline Details - Coherus' oncology pipeline features multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is currently in Phase 1 studies for advanced solid tumors, including head and neck squamous cell carcinoma and gastric cancer [7] - Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors, including non-small cell lung cancer and hepatocellular carcinoma [7]

Core Insights - Coherus BioSciences, Inc. will be webcasting its participation in several upcoming conferences, providing access to presentations via its Investor Events section on the company website [1][2] - The company is a fully integrated commercial-stage innovative oncology firm with an approved PD-1 inhibitor, LOQTORZI®, and a promising pipeline of mid-stage clinical candidates targeting various cancers [4] - Coherus' immuno-oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses against tumors, with ongoing studies for novel treatments [5] Company Overview - Coherus is focused on growing sales of LOQTORZI in nasopharyngeal carcinoma and advancing new indications in combination with pipeline candidates and partners [4] - The company has a robust immuno-oncology pipeline, including Casdozokitug, an IL-27 antagonistic antibody, and CHS-114, a selective anti-CCR8 antibody, both in various stages of clinical trials [5] Upcoming Events - Coherus will participate in the Citizens Life Science Conference on May 8, 2025, at 9:00 a.m. EDT [6] - The company will also present at the HCW BioConnect @ Nasdaq NYC 2025 on May 20, 2025, at 12:00 p.m. EDT [6] - Additional participation includes the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 4, 2025 [6]